Early or deferred initiation of efavirenz during rifampicin-based TB therapy has no significant effect on CYP3A induction in TB-HIV infected patients.

Eleni AklilluAlimuddin ZumlaAbiy HabtewoldWondwossen AmogneEyasu MakonnenGetnet YimerJürgen BurhenneUlf Diczfalusy

Published in: British journal of pharmacology (2020)

This article is part of a themed issue on Oxysterols, Lifelong Health and Therapeutics. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v178.16/issuetoc.

Keyphrases

hiv infected patients
mycobacterium tuberculosis
antiretroviral therapy
healthcare
hiv infected
public health
pulmonary tuberculosis
small molecule
health information
benign prostatic hyperplasia
stem cells
risk assessment
replacement therapy